News

Fetal complications are about four times more common in pregnant women with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD), than in those without the autoimmune condition, according to a small study. Still, maternal complications occurred at similar rates, and most were directly linked to AIHA relapses, or…

Note: This story was updated Jan. 30, 2023,  to correct that the CARDINAL trial did not include a placebo group. The U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for Enjaymo (sutimlimab-jome) to include cold agglutinin disease (CAD) patients without a history of…

Special considerations should be taken when preparing a blood transfusion for someone with cold agglutinin disease (CAD), a recent study indicates. The study, “Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies,” was published…

A new case study reports the rare co-occurrence of cold agglutinin disease (CAD) and blood cancer in a man in Iran. The patient, 56, who had been diagnosed with myelodysplastic syndrome (MDS), an umbrella term for a group of rare blood cancers, was found to also have CAD…

Multiple strategies to keep a woman with cold agglutinin disease (CAD) sufficiently warm right before and during hip replacement surgery allowed for a safe procedure and the absence of post-surgery complications, a case study shows. One way to reduce heat loss — and therefore prevent disease worsening — was…

Individuals with cold agglutinin disease (CAD) face greater risks of mental health problems, with patients 60% more likely than healthy people to receive medical attention for anxiety or depression, according to a new U.S. study. The data referred to a combined risk of requiring either a hospital visit for…

People with cold agglutinin disease (CAD) reported clinically significant improvements in health-related quality of life after treatment with Enjaymo (sutimlimab-jome), according to a new analysis of data from the Phase 3 CADENZA clinical trial. These findings “further augment the primary efficacy outcomes of the placebo-controlled Phase 3 CADENZA…

Even with treatment, many people with cold agglutinin disease (CAD) continue to experience moderate or severe anemia and hemolysis events caused by red blood cell destruction, a new analysis found. “Despite high proportions of patients receiving CAD-related therapies during the first year following diagnosis, the number of moderate/severe anemia…

Enjaymo (sutimlimab-jome) has been approved by the European Commission (EC) to treat anemia caused by the loss of red blood cells — called hemolytic anemia — in adults with cold agglutinin disease (CAD). The EC’s decision to approve the therapy, the first and only approved therapeutic option for…

A woman with cold agglutinin disease (CAD) secondary to a cancer also developed bilateral retinal vasculitis — inflammation of the blood vessels found at the back of both eyes — in what researchers claim to be “the first report of retinal vasculitis in a patient with CAD.” Initial treatment…